BioSpace News Archive

The board of directors of Eli Lilly and Company announced a 15 percent increase in its quarterly dividend.

Arrowhead Pharmaceuticals Inc. announced that as an inducement to entering into employment with the Company, on December 6, 2019, the Compensation Committee of the Board of Directors approved “inducement” grants to 21 new employees under Rule 5635 of the NASDAQ Marketplace Rules.

Mr. Kollu joins GRAIL from Illumina, Inc. where he most recently served as Vice President, Global Market Development and led the teams that drove the commercial adoption of genomics in multiple applications including noninvasive prenatal testing and liquid biopsy.

A paper demonstrating Spheryx’s xSight’s ability to provide new insights into complex particles has been published in the journal Soft Matter.

The Phase 4 clinical study is titled “A Multicenter, Open-Label Study to Assess the Efficacy and Safety of Acthar Gel in Subjects with Severe Keratitis.”

Dr. Patricio Stocker will continue to support Blueberries as a Senior Strategic Consultant focused on expanding the Company’s international cannabis sales and other strategic initiatives.

Praxis Communications, a full-service patient recruitment agency that specializes in optimizing patient enrollment for research studies, announces it has completed its certification under the Asia-Pacific Economic Cooperation Cross Border Privacy Rules system (APEC CBPRs), a member-backed data privacy certification that bridges differing national privacy laws that companies can join to demonstrate their accountability within the APEC region.

Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today announced the appointment of Richard Scheller, Ph.D., and Thomas Südhof, M.D., as co-chairs of the Company’s Strategic Portfolio Advice and Review Committee (SPARC).

Reported results from analysis of the Phase 1b study of AL001 in patients with symptomatic FTD-GRN showing a statistically significant normalization in a number of disease-associated proteins and an initial trend of a decrease compared to baseline levels in plasma Neurofilament

Eiger BioPharmaceuticals, Inc. announced that it has initiated submission of a New Drug Application for Lonafarnib for the treatment of Hutchinson-Gilford Progeria Syndrome and Progeroid Laminopathies to the U.S. Food & Drug Administration under the Rolling Review Process.